Viz.ai, Inc., the leading applied artificial intelligence healthcare company, is excited to highlight Dr. Vitor Mendes Pereira’s presentation “Artificial Intelligence to Improve the Detection and Triage of Cerebral Aneurysms”, which outlines the development of the Viz.ai algorithm to detect cerebral aneurysms at the International Stroke Conference in Los Angeles on Thursday (Feb. 20th) at 4:15pm PST in Room 515B.
Dr. Mendes Pereira, Toronto Western Hospital, along with other research collaborators around the world and some of the top artificial intelligence (AI) developers in healthcare, has developed an algorithm to detect cerebral aneurysms. The results of this collaboration, including the accuracy, will be shown during the presentation.
“Viz.ai’s development utilizing deep learning, artificial intelligence is nothing short of ground-breaking. By applying their technology to aneurysms, clinicians like myself will now be able to better triage patients throughout our hospital network,” said Dr. Mendes Pereira.
Dr. Mendes Pereira has been extensively involved in the treatment of complex neurovascular diseases (including large and giant aneurysms), curative treatment of arteriovenous malformations, dural arteriovenous malformations, paraspinal and spinal vascular disorders, and pediatric vascular malformations. He is currently one of the principal investigators (PI) for the Stryker EndoVascular Treatment Of Wide-Neck Aneurysms, an EvaLuation of Safety and EffectiVeness of Stryker SurpassEvolve™ Flow Diverter System (EVOLVE) study. He is also leading clinical research on stroke as global co-PI for the STAR trial, European interventional PI for the SWIFT-PRIME study and international PI for the SWIFT DIRECT trial.
“AI-based aneurysm detection and analysis continues Viz.ai’s commitment to bring cutting edge technology to clinicians and help them prevent devastating outcomes. We are delighted to support the work of leading investigators like Dr. Mendes Pereira as they continue to seek better treatment pathways for their patients,” said Chris Mansi CEO and Co-Founder of Viz.ai.
An aneurysm is a localized enlargement of an artery caused by a weakening of the artery wall. An estimated 6.5 million people in the United States have an unruptured brain aneurysm, or 1 in 50 people. The most significant health problems result from aneurysms that rupture, with 25% of ruptures leading to death within 24 hours. Characteristics such as size, location, and growth during follow-up evaluation may affect the risk that an aneurysm will rupture, making careful diagnosis key to understanding the need for treatment.
Viz.ai is the leader in applied artificial intelligence in healthcare. Viz.ai’s mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment and improve access to care. Viz.ai’s flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about suspected stroke patients straight to a specialist who can intervene and treat.
In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO, the first-ever computer-aided triage and notification software. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral perfusion image analysis.
Viz.ai is located in San Francisco and Tel Aviv.